Sentence examples for baseline did not predict from inspiring English sources

Degree of insight at baseline did not predict response to sertraline, i.e., patients with poor insight were just as likely to respond to sertraline as patients with good insight.

Statin use at baseline did not predict incidence of dementia or AD (adjusted hazard ratio for dementia, 1.19; 95% confidence interval, 0.53-2.34; adjusted hazard ratio for AD, 1.19; 95% confidence interval, 0.35-2.96), nor did statin use at follow-up (adjusted odds ratio for dementia, 1.04; 95% confidence interval, 0.56-1.81; adjusted odds ratio for AD, 0.85; 95% confidence interval, 0.32-1.88).

One possible explanation could be that a very small proportion of patients underwent liver transplantation; (2) short-term mortality was well predicted by ICU scores, which reflect the degree of organ dysfunction; (3) bad ICU score results at baseline did not predict 6-month mortality in ICU survivors.

BMI, hsCRP or serum Vitamin D level at baseline did not predict improvement in headache disability.

The presence of anti-CCP2 or IgM RF at baseline did not predict these outcomes.

Severe vitamin D deficiency at baseline did not predict progression to microalbuminuria or macroalbuminuria.

As the mechanisms that determine response and resistance to anti-angiogenic agents are complex (Bergers and Hanahan, 2008; Ebos et al, 2009; Bottsford-Miller et al, 2012; Sennino and McDonald, 2012), it is perhaps not surprising that tumour vessel density at baseline does not predict response to anti-angiogenic therapy.

Baseline body weight and baseline BMI did not predict degree of weight loss achieved with the diet.

Fidaxomicin susceptibility of baseline isolates did not predict clinical cure, failure, or recurrence for fidaxomicin (baseline MIC90, 0.25 µg/mL [range, ≤0.008 1 µg/mL]).

Baseline CRP did not predict CVD over 3.8 years of follow-up (HRper SD log 0.89 [95% CI 0.75, 1.06]), whereas baseline LDL-cholesterol predicted CVD (HRper SD 1.21 [95% CI 1.02, 1.44]), as did on-treatment LDL-cholesterol.

In our case series, baseline variables did not predict a favorable effect or adverse effects from BoNT-A therapy.